Global Peptide Therapeutics Market Report 2021: Market to Reach $47 Billion by 2027 - Innovative Segment to Account for $$28 Billion of the Total Market - ResearchAndMarkets.com

The "Peptide Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Peptide Therapeutics Market to Reach $47 Billion by 2027

Amid the COVID-19 crisis, the global market for Peptide Therapeutics estimated at US$27.2 Billion in the year 2020, is projected to reach a revised size of US$47 Billion by 2027, growing at a CAGR of 8.1% over the period 2020-2027.

Innovative, one of the segments analyzed in the report, is projected to record 6.6% CAGR and reach US$28 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 10.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $7.4 Billion, While China is Forecast to Grow at 12.3% CAGR

The Peptide Therapeutics market in the U.S. is estimated at US$7.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2027 trailing a CAGR of 12.1% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 46 Featured):

• AbbVie, Inc.
• Advanced Accelerator Applications SA
• Akashi Therapeutics, Inc.
• Amgen, Inc.
• Anthera Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bachem AG
• Bristol-Myers Squibb Company
• Cardiorentis AG
• Corden Pharma International GmbH
• Debiopharm Group
• Derma Sciences, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Hanmi Pharmaceutical Co., Ltd.
• Insmed, Inc.
• Ipsen Group
• Johnson & Johnson
• Lonza Group AG
• Mallinckrodt PLC
• Merck & Co., Inc.
• MolMed S.p.A.
• Novartis AG
• Novo Nordisk A/S
• Nymox Pharmaceutical Corporation
• PAR Pharmaceutical Companies, Inc.
• PeptiDream Inc.
• Pfizer, Inc.
• PolyPeptide Group
• Radius Health, Inc.
• Repligen Corporation
• Sanofi SA
• SciClone Pharmaceuticals Holding Limited.
• Shire PLC
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• The Medicines Company
• X-GEN Pharmaceuticals, Inc.
• Zealand Pharma A/S
• Zydus Cadila

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

• UNITED STATES
• CANADA
• JAPAN
• CHINA
• EUROPE
• FRANCE
• GERMANY
• ITALY
• UNITED KINGDOM
• SPAIN
• RUSSIA
• REST OF EUROPE
• ASIA-PACIFIC
• AUSTRALIA
• INDIA
• SOUTH KOREA
• REST OF ASIA-PACIFIC
• LATIN AMERICA
• ARGENTINA
• BRAZIL
• MEXICO
• REST OF LATIN AMERICA
• MIDDLE EAST
• IRAN
• ISRAEL
• SAUDI ARABIA
• UNITED ARAB EMIRATES
• REST OF MIDDLE EAST
• AFRICA

IV. COMPETITION

• Total Companies Profiled: 46

For more information about this report visit https://www.researchandmarkets.com/r/x0hlr0

View source version on businesswire.com: https://www.businesswire.com/news/home/20210611005279/en/